How to Buy Corcept Therapeutics Stock
Corcept Therapeutics Inc
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.
Corcept Therapeutics stock last closed at $23.00, down 1.67% from the previous day, and has increased 2.4% in one year. It has overperformed other stocks in the Biotechnology industry by 0.28 percentage points. Corcept Therapeutics stock is currently +10.21% from its 52-week low of $20.87, and -32.9% from its 52-week high of $34.28.
At the moment, there are 103.52M CORT shares outstanding. The market value of CORT is $2.38B. In the last 24 hours, 957,823 CORT shares were traded.
How to Buy Corcept Therapeutics Stock
Not sure how to invest in Corcept Therapeutics stock? Here's how.
- Figure out where to buy Corcept Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Corcept Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit money your investment account: Pick your method of payment and add your info.
- Evaluate Corcept Therapeutics stock: The Corcept Therapeutics ticker symbol is CORT. Is Corcept Therapeutics stock a good investment? Should you buy shares of CORT? How do CORT's underlying business fundamentals look? Do top analysts think Corcept Therapeutics is a good buy? Why has CORT's stock price moved recently? (Hint: Our stock market research website can help you evaluate if CORT is a good stock to buy).
- Execute your CORT buy order: Decide if you will purchase CORT shares at the current market price or use a limit order to purchase CORT stock at a specific price.
- Watch your CORT investment: Create a watchlist to get the latest news on your new investment in Corcept Therapeutics shares.
Step 1: Figure out where to buy Corcept Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy CORT shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Healthcare, New York to London — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal details so you can invest in CORT today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start your new trading account.
- Submit your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have opened your account on stock market apps, you can securely and quickly fund your account:
Check out this video walkthrough if you need help transferring money into your investment account.
Step 4: Evaluate Corcept Therapeutics stock
Once you have identified the best place to buy Corcept Therapeutics stock, it's important to research their stock before you invest, so you actually wrap your head around the risk and upside.
Corcept Therapeutics Numbers
Fundamentals of CORT
WallStreetZen was designed to help average investors perform more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on CORT's stock page.
Is CORT stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge CORT's true value.
Using relative valuations methods:
- CORT could be overvalued based on its P/E ratio of 22.55x, relative to Biotechnology industry P/E ratio of 15.83x
- CORT could be undervalued based on its P/B ratio of 4.7x, relative to Biotechnology industry P/B ratio of 5.83x
- CORT may be undervalued based on its PEG ratio of 0.75x
You can do additional valuation analysis on CORT's stock here.
CORT Financial Health Summary
Positive Health Checks:
- CORT earnings of $106.64M is not enough to cover its interest payments.
- CORT's operating cash flow of $127.04M allows it to safely service it's debt of $151.00k.
- There are more short-term assets than long-term liabilities on the CORT balance sheet.
- There are more short-term assets than short-term liabilities on the CORT balance sheet.
- CORT has a low debt to equity ratio of 0.23.
Negative Health Checks:
- Total CORT debt is higher than 5 years ago, relative to shareholder equity.
- CORT profit margin has gone down from 25.2% to 21.9% in the past year.
Is it a good time to buy Corcept Therapeutics stock, according to analysts?
Out of 3 Wall Street analysts who give recommendations on CORT, the consensus analyst rating on CORT is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Corcept Therapeutics stock forecast page.
CORT Momentum
CORT Performance Numbers
Last year, CORT earnings were $105.50M. Over the last five year, CORT's earnings have gone up by 9.43% per year. This was slower than the Biotechnology industry average of 15.76%.
Last year, CORT revenue was $482.38M. During the last 5 year, CORT's revenue has gone up by 13.93% per year. This was slower than the Biotechnology industry average of 29.02%.
Dive into CORT's earnings and revenue performance here.
What are CORT executives and large shareholders up to?
Over the past year, executives and large shareholders at CORT have bought more shares than they have sold.
David L. Mahoney, Director of CORT, was the latest CORT insider to sell. They sold $52,217.20 worth of CORT stock on Apr 10, 2024.
Dig into more about who owns CORT stock here.
Does CORT stock generate passive income?
No, Corcept Therapeutics doesn't provide an income stream by paying out dividends.
CORT Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your CORT buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific dollar amount, use a limit order.
Click the Open Trade button and your broker will execute your order.
If you need additional assistance investing in stocks on eToro, watch the helpful video below:
Step 6: Watch your CORT investment
Now that you own some CORT stock, you'll want to keep up with your new investment.
Create a watchlist to get notified of important updates regarding your CORT stock.
CORT Feed
How to Buy Stock in Corcept Therapeutics
To summarize, here are the 6 steps you need to take to buy Corcept Therapeutics stock right now:
- Figure out where to buy Corcept Therapeutics stock
- Open a brokerage account
- Deposit money your investment account
- Evaluate Corcept Therapeutics stock
- Execute your CORT buy order
- Watch your CORT investment
If you are looking for a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your new investment in Corcept Therapeutics, click below.
More Content You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.